2 Patented platforms

In a world where healthcare is constantly evolving, the need for new therapeutics and preventives has never been more critical. PROTEIX Biotech stands at the forefront of this revolution, dedicated to developing innovative solutions using its "Plug and Play" platforms. PROTEIX Biotech innovations are based on engineering already approved and safe biologics to transform them into "Plug and Play" genetic codes for application in many areas. This blog post delves into our platforms, showcasing their potential for reshaping the landscape of healthcare.

A summary of one of the PROTEIX "Plug and Play" platforms and how it is used

A. "Plug and Play" antibody-mimetic molecular assembly platform

Our first platform is based on a safe, widely used protein nanocage called ferritin. It is a hollow spherical-shaped protein made of 24 subunits. Using our proprietary engineering methodology, we converted the genetic code of each subunit into that of an antibody-mimetic precursor comprising two constant domains linked by a linker peptide and a variable N-terminal domain inserted into the constant domain via a peptide arm. The linker peptide between the two constant domains encodes the sequence recognized by a site-specific protease. Consequently, the genetic code is used to express each precursor, and protease cleavage of the precursors yields nanocages decorated with multiple variable domains.

The image shows our approach to engineer a safe protein nanocage and create a "plug and play" genetic code as precursors to construction of different therapeutics targeting various biological entities such as viruses, cancer, or bacteria.

The variable domain can be rapidly changed and replaced by targeting ligands, antibody domains, antigens, or therapeutic proteins. The peptide arm could be designed for site-specific small-molecule or protein conjugation, and the C-terminus can be modified to include therapeutic peptides. The protease cleavage assembly can be used to encapsulate hydrophilic or hydrophobic drugs.

The image describes how our "plug and play" platform technology can be used. Different DNA sequences can be plugged into our platform. The resulting DNA sequence can then be used to construct and assemble multifunctional therapeutics or preventives, such as vaccines, cancer chemotherapeutic agents, or targeted drug delivery vehicles.

B. "Plug and Play" restriction factor enzymes for antiviral therapy

By engineering human enzymes, we have created humanized multidomain viral restriction factor enzymes. These enzymes are being tested and developed for gene therapy to create a synthetic innate immune system that can prevent or treat viral infections.

The scheme shows a synthetic innate immune system made from engineered humanised restriction factors with broad-spectrum antiviral activity.